News9 months ago
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
eFFECTOR Therapeutics, Inc. Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross...